Condor Capital Management Abb Vie Inc. Transaction History

Condor Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $7.42 Million - $9.39 Million	-69,063 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$106.4 - $120.78 $107,783 - $122,350	-1,013 Reduced 1.45%	69,063 $7.45 Million
Q1 2021 May 10, 2021	SELL	$102.3 - $112.62 $73,962 - $81,424	-723 Reduced 1.02%	70,076 $7.58 Million
Q3 2020 Nov 09, 2020	SELL	$85.91 - $100.83 $14,003 - $16,435	-163 Reduced 0.23%	70,799 $6.2 Million
Q2 2020 Aug 07, 2020	BUY	$73.37 - $98.18 $17,682 - $23,661	241 Added 0.34%	70,962 $6.97 Million
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $127,814 - $159,923	-1,772 Reduced 2.44%	70,721 $6.26 Million
Q3 2019 Nov 06, 2019	SELL	$62.98 - $75.72 $4.67 Million - $5.62 Million	-74,204 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$65.7 - $83.98 $3,285 - $4,199	50 Added 0.07%	74,204 $5.4 Million
Q4 2018 Feb 08, 2019	SELL	$77.85 - $96.01 $23,588 - $29,091	-303 Reduced 0.41%	74,154 $6.84 Million
Q3 2017 Nov 08, 2017	BUY	$69.85 - $89.22 $5.2 Million - $6.64 Million	74,457	74,457 $6.62 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Condor Capital Management, based on Form 13F filings with the SEC.

Stay updated on Condor Capital Management with notifications on news.